UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2585-2592

2012

Volltextzugriff (PDF)

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1124-1130

2010

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3113-3122

2017

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Cancer, 2007-09, Vol.110 (5), p.965-972

2007

Volltextzugriff (PDF)

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Clinical cancer research, 2007-02, Vol.13 (4), p.1198-1207

2007

Volltextzugriff (PDF)

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Clinical cancer research, 2008-12, Vol.14 (23), p.7871-7877

2008

Volltextzugriff (PDF)

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2889-2895

2003

Volltextzugriff (PDF)

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2179-2182

2012

Volltextzugriff (PDF)

Past, present, and future challenges in breast cancer treatment

Journal of clinical oncology, 2014-07, Vol.32 (19), p.1979-1986

2014

Volltextzugriff (PDF)

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1232-1235

Burstein, Harold J

2011

Volltextzugriff (PDF)

Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2001-05, Vol.19 (10), p.2722-2730

2001

Volltextzugriff (PDF)

Novel Agents and Future Directions for Refractory Breast Cancer

Seminars in oncology, 2011-06, Vol.38, p.S17-S24

Burstein, Harold J

2011

Volltextzugriff (PDF)

Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2142-2150

2014

Volltextzugriff (PDF)

Introduction: Current and Future Approaches to Chemotherapy in Patients With Resistant Breast Cancer

Seminars in oncology, 2011-06, Vol.38, p.S1-S2

2011

Volltextzugriff (PDF)

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Journal of clinical oncology, 2022-02, Vol.40 (5), p.449-458

2022

Volltextzugriff (PDF)

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

Journal of clinical oncology, 2023-03, Vol.41 (7), p.1370-1375

2023

Volltextzugriff (PDF)

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.297-304

2016

Volltextzugriff (PDF)

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)

Journal of clinical oncology, 2014-12, Vol.32 (35), p.3959-3966

2014

Volltextzugriff (PDF)

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Breast (Edinburgh), 2013-08, Vol.22 (4), p.525-531

2013

Volltextzugriff (PDF)

Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy

Journal of clinical oncology, 2005-11, Vol.23 (33), p.8340-8347

2005

Volltextzugriff (PDF)

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Journal of clinical oncology, 2014-08, Vol.32 (22), p.2311-2317

2014

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Aktive Filter

ThemaChemotherapy

ThemaAntineoplastic Combined Chemotherapy Protocols - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(52)

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Past, present, and future challenges in breast cancer treatment

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

Novel Agents and Future Directions for Refractory Breast Cancer

Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study

Introduction: Current and Future Approaches to Chemotherapy in Patients With Resistant Breast Cancer

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Aktive Filter

Suchergebnisse filtern